UK specialty company Alliance Pharma has appointed two new country managers.
Dr Philippe Pasdelou will manage operations in France, while Lars Börger will lead the company’s teams in Germany, Switzerland and Austria.
At the same time the company announced its acquisition of three antimalarial drugs from AstraZeneca for £4.2m and up to £1m in future sales royalties.
The brands – Paludrine, Avoclor and Savarine – are sold predominately in the UK and France and are expected to generate approximately £1.1m per year to Alliance’s balance sheet.
“We are delighted to add these important antimalarial brands to the Alliance portfolio, and at the same time to have appointed such highly experienced executives as Philippe Pasdelou and Lars Börger to spearhead our expansion in mainland Europe,” said John Dawson, chief executive of Alliance Pharma.
The company said both Pasdelou and Börger would initially focus on securing acquisition and in-licensing opportunities across Europe.
Börger was most recently licensing director at Grünenthal and has experience across a number of pharmaceutical and medical device companies, in both strategic and operational roles.
Meanwhile, Pasdelou has managed several pharmaceutical companies in France and other countries and his experience includes setting up a company with a similar business model to Alliance.